Yüklüyor......
Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors
Background: The presented phase I, first-in-human study evaluated the tolerance, pharmacokinetics, and preliminary efficacy of larotinib mesylate in patients with advanced solid tumors. Methods: Cancer patients were assigned to receive larotinib mesylate at 50–400 mg dose levels until disease progre...
Kaydedildi:
| Yayımlandı: | Front Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930822/ https://ncbi.nlm.nih.gov/pubmed/33679419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.636324 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|